Myovant Sciences GmbH   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: London United Kingdom (2016)
Status: Acquired by Sumitomo Dainippon (2019)

Organization Overview

First Clinical Trial
2016
NCT04978688
First Marketed Drug
2020
relugolix
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Myovant Sciences | MYOVANT SCIENCES | Myovant Sciences GmbH

Active Ingredients

Marketed Drugs (3)

estradiol (progynon depot) (2021)

norethindrone (2021)

relugolix (2020)

Drugs in Phase 4 Trials (1)

estradiol (progynon depot) (8 trials)

Drugs in Phase 3 Trials (3)

leuprolide (lupron) (2 trials)

norethindrone (8 trials)

relugolix (13 trials)

Drugs in Phase 1 Trials (4)

abiraterone (zytiga) (1 trial)

erythromycin (ilosone) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Endometriosis (Phase 3)

Hemorrhage (Phase 3)

Hypersensitivity (Phase 1)

Leiomyoma (Phase 3)

Menorrhagia (Phase 3)

Myofibroma (Phase 3)

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 8